A data set based on a meta-analysis comparing overall survival times between individuals randomized to experimental arms and comparator arms in randomized trials for non-small cell lung cancer therapies (Iskander et al. 2024).
dat.lung
A data frame with 30 rows and 11 columns:
study | National Clinical Trial (NCT) number of the study. |
n.g1 | number of subjects (experimental group). |
med.g1 | median overall survival (experimental group). |
med.ci.lb.g1 | lower confidence interval bound around the median (experimental group). |
med.ci.ub.g1 | upper confidence interval bound around the median (experimental group). |
med.ci.level.g1 | level of the confidence interval (experimental group). |
n.g2 | number of subjects (comparator group). |
med.g2 | median overall survival (comparator group). |
med.ci.lb.g2 | lower confidence interval bound around the median (comparator group). |
med.ci.ub.g2 | upper confidence interval bound around the median (comparator group). |
med.ci.level.g2 | level of the confidence interval (comparator group). |
Iskander, R., Moyer, H., Fergusson, D., McGrath, S., Benedetti, A., and Kimmelman, J. (2024). The benefits and risks of receiving investigational solid tumor drugs in randomized trials: A systematic review and meta-analysis. Annals of Internal Medicine. 177(6)759-767.